Cadila Healthcare Ltd has announced that the USFDA inspected the Company's manufacturing facilities located at St. Louis, MO, USA of Nesher Pharmaceuticals (USA) LLC (100% subsidiary of Zydus Pharmaceuticals USA), from 13th May to 31St May, 2019. The inspection concluded with 3 observations at one facility and 8 observations at the other facility of Nesher Pharmaceuticals with a recommendation for 'Voluntary Action Indicated (VAI)'.
This was a product specific pre-approval inspection with general cGMP and there were no Data Integrity (DI) related observations. The Company is confident of addressing these observations and responding to the USFDA at the earliest.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.257.3 as compared to the previous close of Rs. 263.65. The total number of shares traded during the day was 138968 in over 2319 trades.
The stock hit an intraday high of Rs. 266 and intraday low of 254.05. The net turnover during the day was Rs. 35868723.